Finally, recent observational studies have shown that adjuvant low-dose aspirin improved survival in patients with PIK3CA-mutant tumors [85-87]; this sensitivity requires further prospective evaluation and could be at least partially explained by the fact that PI3K-AKT seems to induce NF-ĸB-dependent transcriptional upregulation of COX2, which has been demonstrated to display pro-survival activity in CRC cells [87-89]. This evidence concerns the gene PIK3CA and colorectal carcinoma.